Dyadic International INC

Dyadic International announced that Nasdaq has confirmed the company has regained compliance with listing rules, ensuring its continued listing on the Nasdaq Capital Market.

Dyadic International received a notification from Nasdaq that could lead to the delisting of its securities due to non-compliance with minimum bid price and continued listing standards.

Dyadic International highlights accelerated interest in its C1 biomanufacturing platform driven by Ebola preparedness activities and expanding commercial adoption across various life science sectors.

Dyadic International has entered a research collaboration with Scripps Research to evaluate C1-platform-based antibody and vaccine candidates for hantaviruses.

Dyadic International announced its first quarter 2026 financial results, highlighting significant progress in commercial partnerships and product development, alongside a notable increase in revenue.

Dyadic International, Inc. received a Nasdaq deficiency notice for failing to meet continued listing requirements, including minimum stockholders' equity.

Dyadic International's Q1 2026 report shows a significant 182.3% revenue increase driven by research and development, grant, and license/milestone revenues, alongside a narrowed net loss.

Dyadic International, Inc. reported a significant increase in net loss for Q3 and the nine months ended September 30, 2025, despite securing new grants and completing a public offering to fund its strategic shift towards commercializing non-therapeutic protein platforms.

Dyadic International, Inc. (DYAI) reported a reduced net loss and increased total revenue for Q2 2025, while addressing Nasdaq compliance and securing $5.3 million in post-period capital.

Dyadic International, Inc. released its first quarter 2025 financial results, marked by decreased revenue and a net loss, but with sufficient cash reserves for the next twelve months.

Dyadic International's strategic focus on licensing and collaboration agreements fuels revenue growth in the third quarter of 2024, despite ongoing investments in research and development.

Dyadic International's Q2 2024 results reflect a strategic shift towards commercialization, with decreased revenue due to winding down research collaborations, offset by progress in non-pharmaceutical partnerships and a recent capital raise.

Dyadic International, Inc. rebranded as Dyadic Applied BioSolutions, shifting its strategy to commercialize non-pharmaceutical proteins while reporting a wider net loss in 2025 despite new grant funding.

Dyadic International's 10-K filing reveals a year of strategic shifts, including expansion into alternative proteins and continued development of its C1 platform for pharmaceutical applications, alongside financial results reflecting ongoing investments and collaborations.

Dyadic International has issued stock options and restricted stock units to employees, directors, and consultants under its 2021 Equity Incentive Award Plan.

Francisco Trust under agreement dated February 28, 1996 reported changes in beneficial ownership of Dyadic International Inc common stock on July 22, 2026.

Francisco Trust, a 10% owner and director of Dyadic International Inc., reported transactions involving common stock and convertible notes.

Dyadic International's VP of Research and Business Development, Ronen Tchelet, acquired 18,064 shares of common stock and 47,250 stock options as part of his compensation.

Dyadic International's CFO, Ping Rawson, increased her beneficial ownership through the vesting of 29,158 common shares from RSUs and an annual grant of 47,250 stock options.

Dyadic International Director Patrick K. Lucy reported significant equity transactions, including the settlement of restricted stock units and new grants of stock options and restricted stock units.

Dyadic International Director Jack Kaye reported the settlement of previously vested restricted stock units into common stock and received new annual grants of stock options and restricted stock units.

Dyadic International, Inc. has filed a definitive proxy statement with the SEC.

Dyadic International announces its 2025 Annual Meeting of Shareholders to be held virtually on June 20, 2025, featuring proposals including director election, auditor ratification, and executive compensation advisory votes.

Dyadic International, Inc. has filed a definitive proxy statement with the SEC.

Dyadic International announces its 2024 Annual Meeting of Shareholders to be held virtually on June 11, 2024, covering director elections, auditor ratification, and executive compensation.

Francisco Trust amends Schedule 13G filing, reporting 11.58% ownership of Dyadic International's common stock.

Francisco Trust, managed by Thomas Emalfarb, has updated its beneficial ownership of Dyadic International Inc. common stock, now holding 11.97% after a convertible note amendment.

Francisco Trust, managed by Thomas Emalfarb, has reported beneficial ownership of 11.97% of Dyadic International's common stock as of March 31, 2026.

Mark A. Emalfarb, CEO of Dyadic International Inc., reported an increased beneficial ownership of 16.6% of the company's common stock, including shares from options and a convertible note.

Bandera Partners LLC and its managing members filed an amended Schedule 13G, disclosing a 4.6% beneficial ownership stake in Dyadic International Inc.

Francisco Trust, through its trustee Thomas Emalfarb, has reported a passive beneficial ownership of 11.52% in Dyadic International Inc.'s common stock as of December 31, 2024.